Journal of Clinical Lipidology

Aims & Scope

Because the scope of clinical lipidology is broad, the topics addressed by the Journal are equally diverse.

Typical articles explore lipidology as it is practiced in the treatment setting, recent developments in pharmacological research, reports of treatment and trials, case studies, the impact of lifestyle modification, and similar academic material of interest to the practitioner.

While preference is given to material of immediate practical concern, the science that underpins lipidology is forwarded by expert contributors so that evidence-based approaches to reducing cardiovascular and coronary heart disease can be made immediately available to our readers.

Sections of the Journal will address pioneering studies and the clinicians who conduct them, case studies, ethical standards and conduct, professional guidance such as ATP and NCEP, editorial commentary, letters from readers, National Lipid Association (NLA) news and upcoming event information, as well as abstracts from the NLA annual scientific sessions and the scientific forums held by its chapters, when appropriate.

View Aims & Scope

---

Metrics & Ranking

Impact Factor

Year	Value
2025	4.6
2024	3.60

Journal Rank

Year	Value
2024	3224

Journal Citation Indicator

Year	Value
2024	1155

SJR (SCImago Journal Rank)

Year	Value
2024	1.267

Quartile

Year	Value
2024	Q1

h-index

Year	Value
2024	79

---

---

Abstracting & Indexing

Journal is indexed in leading academic databases, ensuring global visibility and accessibility of our peer-reviewed research.

• Scopus
• Google Scholar
• Web of Science

---

Subjects & Keywords

Journal’s research areas, covering key disciplines and specialized sub-topics in Medicine and Nursing, designed to support cutting-edge academic discovery.

---

Most Cited Articles

The Most Cited Articles section features the journal's most impactful research, based on citation counts. These articles have been referenced frequently by other researchers, indicating their significant contribution to their respective fields.

• National Lipid Association Recommendations for Patient-Centered Management of Dyslipidemia: Part 1—Full Report

  Citation: 642

  Authors: Terry A., Matthew K., Kevin C., Carl E., Harold E., Peter H., James M., Scott M., Edward A., Robert A., Don P., W. Virgil

• Use of Lipoprotein(a) in clinical practice: A biomarker whose time has come. A scientific statement from the National Lipid Association

  Citation: 418

  Authors: Don P., Terry A., Peter H., Marlys L., Catherine J., Børge G., Carl E.

• National Lipid Association Recommendations for Patient-Centered Management of Dyslipidemia: Part 2

  Citation: 414

  Authors: Terry A., Kevin C., Carl E., Peter H., Penny, Geeta, Ralph, Stephen R., Don P., Pamela B., Robert A., Scott M., Martha, Keith C., Krishnaswami, Prakash C., Judith A., Katherine P., James M., Joyce L., Lynne T., Matthew K., Harold E., W. Virgil

• Obesity, adiposity, and dyslipidemia: A consensus statement from the National Lipid Association

  Citation: 409

  Authors: Harold E., Peter P., Penny M., Nicola, Louis J., W. Virgil, J. Michael, Steven R., Rekha, Ralph, Varman T.

• Efficacy and safety of alirocumab vs ezetimibe in statin-intolerant patients, with a statin rechallenge arm: The ODYSSEY ALTERNATIVE randomized trial

  Citation: 402

  Authors: Patrick M., Paul D., Christopher P., John R., Jean, Franklin J., Eric, Terry A., Stephen L., Marie T., Yunling, Robert, Daniel A.

• An assessment by the Statin Muscle Safety Task Force: 2014 update

  Citation: 389

  Authors: Robert S., Steven K., Terry A., Stephen L., Beth A.

• Familial Hypercholesterolemia: Screening, diagnosis and management of pediatric and adult patients

  Citation: 384

  Authors: Anne C., Paul N., Peter P., Christie M., Daniel J., Jennifer G., Stephen R., Samuel S., Sarah D., Matthew K., Mary P., Patrick M., William C., Joyce L., Paul E.

• Understanding Statin Use in America and Gaps in Patient Education (USAGE): An internet-based survey of 10,138 current and former statin users

  Citation: 379

  Authors: Jerome D., Eliot A., Matthew K., Terry A.

• National Lipid Association recommendations for patient-centered management of dyslipidemia: Part 1 – executive summary

  Citation: 372

  Authors: Terry A., Matthew K., Kevin C., Carl E., Harold E., Peter H., James M., Scott M., Edward A., Robert A., Don P., W. Virgil

• LDL particle number and risk of future cardiovascular disease in the Framingham Offspring Study—Implications for LDL management

  Citation: 352

  Authors: William C., James D., Michelle J., Michael J., Lisa, Ramachandran S., Peter W.F., Ralph B.

---